Roche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and "industrialised" drug discovery to find new neuroscience and cancer drugs. The Swiss ...

It might take a while for this AI company to prove its worth, if it ever does so.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec ...

技術進化が著しい現代において、バックエンドエンジニアの採用は企業にとっての大きな挑戦となっています。この課題に応えるべく、Recursion, Inc（共同創業者：田島慎也、Jeffry Alvarado、本社：アメリカカリフォルニア州）は、Recursion転職を立ち上げました。

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.73, representing a -4.64% change from its previous ...

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.32, marking a -3.36% move from the previous day.

Recursion Pharmaceuticals, Inc., a biotechnological firm based in Salt Lake City, Utah, disclosed today that Genentech, Inc. has exercised an option for a Neuroscience Phenomap under a collaboration ...

Why Recursion Pharmaceuticals Is On Investors’ Radar Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this ...